Shares of Community Healthcare Trust surged 9.4% to $14.29 on November 4 after the small-cap healthcare REIT reported third-quarter results that topped Wall Street expectations on both the top and bottom lines, prompting Truist Securities to reiterate its Buy rating and $17 price target. CHCT Delivers a Rare Earnings Surprise and Draws a Bullish Call — But Is a $14 Stock Worth Chasing on a $17 Target?
Shares of Community Healthcare Trust vaulted 9.4% to $14.29 after the small-cap healthcare landlord posted third-quarter results that caught Wall Street off guard, and Truist Securities promptly reaffirmed its confidence in the turnaround story.
• The Numbers Beat the Street by a Wide Margin. FFO — the key profit measure for real estate companies, which strips out non-cash charges like depreciation — came in at $0.54 per share, up 8.2% year-over-year and $0.06 above both Truist's and consensus estimates of $0.48.
Revenue hit $32.4 million, topping the $31.44 million estimate. For a stock that had been drifting lower for months, a clean beat on both lines gave investors a reason to re-engage.
• Occupancy Is Ticking Higher, and That's the Whole Ballgame. Leased occupancy climbed from 89.8% to 90.1% quarter-over-quarter, while general and administrative expenses fell 14.3%.
Truist noted the earnings beat was "driven by higher revenue as portfolio occupancy increased 30 basis points quarter-over-quarter." Each tenth of a percentage point in occupancy means more rent flowing through a largely fixed cost structure. If the trend holds, earnings should keep grinding higher.
• The Dividend Cut Is Funding Growth — Whether the Market Buys It or Not. Earlier this year the company slashed its quarterly payout from $0.48 to $0.33 per share to free up capital. Management is recycling assets — $63 million in recent dispositions — into a $99 million pipeline of higher-yielding acquisitions.
The balance sheet carries 6.0x leverage with no debt maturities before 2028 and over $115 million in liquidity — adequate cushion, though above the sector average. At today's price, the annualized $1.32 dividend still yields roughly 9.2%, well above healthcare REIT peers.
• Even After the Pop, the Stock Sits Well Below Its Analyst Target. The consensus rating among five covering analysts remains a split verdict: one sell, two holds, and two buys. Truist's $17 target implies 19% further upside from here, but Piper Sandler holds a neutral rating with just a $14 target — essentially where the stock sits now. The question is whether improving occupancy and disciplined reinvestment can sustainably close the gap, or whether elevated leverage and tenant concentration risk — particularly in behavioral healthcare — keep the discount in place.
One strong quarter doesn't make a trend. But for a beaten-down REIT yielding over 9% with visible operating improvement, today's reaction suggests the market is starting to price in a comeback.